Survivin downregulation is not required for T antigen knockdown mediated cell growth inhibition in MCV infected merkel cell carcinoma cells

International Journal of Cancer

Volumn 132, Issue 12, 2013, Pages 2980-2982

  Schrama, David ^a,b   Hesbacher, Sonja ^b   Becker, Jürgen C ^a   Houben, Roland ^b  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RETINOBLASTOMA BINDING PROTEIN; SHORT HAIRPIN RNA; SURVIVIN; VIRUS LARGE T ANTIGEN; VIRUS SMALL T ANTIGEN; VIRUS T ANTIGEN;

ANTIGEN EXPRESSION; ANTIGEN FUNCTION; BINDING AFFINITY; BINDING SITE; CELL SURVIVAL; DISEASE ASSOCIATION; DOWN REGULATION; GROWTH INHIBITION; HUMAN; LETTER; MERKEL CELL POLYOMAVIRUS; MERKEL CELL TUMOR; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS;

ANTIGENS, POLYOMAVIRUS TRANSFORMING; CARCINOMA, MERKEL CELL; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; RNA INTERFERENCE; SKIN NEOPLASMS;

EID: 84876131472     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27962     Document Type: Letter

References (10)

1. Lemos B, Nghiem P,. Merkel cell carcinoma: more deaths but still no pathway to blame. J Invest Dermatol 2007; 127: 2100-3.
2. Feng H, Shuda M, Chang Y, Moore PS,. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science 2008; 319: 1096-100.
3. Van Gele M, Moens U,. Merkel cell polyomavirus: a causal factor in merkel cell carcinoma. In:, La Porta C,. Skin Cancers-Risk Factors, Prevention and Therapy. Rijeka: InTech, 2011: 109-41.
4. Houben R, Shuda M, Weinkam R, Schrama D, Feng H, Chang Y, Moore PS, Becker JC,. Merkel cell polyomavirus-infected Merkel cell carcinoma cells require expression of viral T antigens. J Virol 2010; 84: 7064-72.
5. Shuda M, Kwun HJ, Feng H, Chang Y, Moore PS,. Human Merkel cell polyomavirus small T antigen is an oncoprotein targeting the 4E-BP1 translation regulator. J Clin Invest 2011; 121: 3623-34.
6. Houben R, Adam C, Baeurle A, Hesbacher S, Grimm J, Angermeyer S, Henzel K, Hauser S, Elling R, Brocker EB, Gaubatz S, Becker JC, et al. An intact retinoblastoma protein-binding site in Merkel cell polyomavirus large T antigen is required for promoting growth of Merkel cell carcinoma cells. Int J Cancer 2012; 130: 847-56.
7. Arora R, Shuda M, Guastafierro A, Feng H, Toptan T, Tolstov Y, Normolle D, Vollmer LL, Vogt A, Domling A, Brodsky JL, Chang Y, et al. Survivin is a therapeutic target in merkel cell carcinoma. Sci Transl Med 2012; 4: 133ra56.
8. Altieri DC,. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 2008; 8: 61-70.
9. Kim J, McNiff JM,. Nuclear expression of survivin portends a poor prognosis in Merkel cell carcinoma. Mod Pathol 2008; 21: 764-9.
10. Becker JC, Andersen MH, Hofmeister-Muller V, Wobser M, Frey L, Sandig C, Walter S, Singh-Jasuja H, Kampgen E, Opitz A, Zapatka M, Brocker EB, et al. Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunol Immunother 2012; 61: 2091-103.